Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02716805 · FLOW

Participant flow

Phase 1 Study of Tremelimumab, Durvalumab, High-dose Chemotherapy, + Autologous Stem Cell Transplant · Source last updated 2022-10-12

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

groups
  1. description
    "Late" post-autologous stem cell transplant (ASCT) treatment (tremelimumab alone in Cycles 1-2, durvalumab alone in Cycles 3+)
    id
    FG000
    title
    Cohort 1
  2. description
    "Early" post-ASCT treatment (tremelimumab alone in Cycles 1-2, durvalumab alone in Cycles 3+)
    id
    FG001
    title
    Cohort 2
  3. description
    "Late" post-ASCT treatment (tremelimumab + durvalumab in Cycles 1-2, durvalumab alone in Cycles 3+)
    id
    FG002
    title
    Cohort 3
  4. description
    "Early" post-ASCT treatment (tremelimumab + durvalumab in Cycles 1-2, durvalumab alone in Cycles 3+)
    id
    FG003
    title
    Cohort 4
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        2
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      type
      Progressive disease
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        6
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        4
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        2
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study
Complete source fields
groups
  1. description
    "Late" post-autologous stem cell transplant (ASCT) treatment (tremelimumab alone in Cycles 1-2, durvalumab alone in Cycles 3+)
    id
    FG000
    title
    Cohort 1
  2. description
    "Early" post-ASCT treatment (tremelimumab alone in Cycles 1-2, durvalumab alone in Cycles 3+)
    id
    FG001
    title
    Cohort 2
  3. description
    "Late" post-ASCT treatment (tremelimumab + durvalumab in Cycles 1-2, durvalumab alone in Cycles 3+)
    id
    FG002
    title
    Cohort 3
  4. description
    "Early" post-ASCT treatment (tremelimumab + durvalumab in Cycles 1-2, durvalumab alone in Cycles 3+)
    id
    FG003
    title
    Cohort 4
periods
  1. drop Withdraws
    1. reasons
      1. group Id
        FG000
        num Subjects
        2
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      type
      Progressive disease
    milestones
    1. achievements
      1. group Id
        FG000
        num Subjects
        6
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      type
      STARTED
    2. achievements
      1. group Id
        FG000
        num Subjects
        4
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      type
      COMPLETED
    3. achievements
      1. group Id
        FG000
        num Subjects
        2
      2. group Id
        FG001
        num Subjects
        0
      3. group Id
        FG002
        num Subjects
        0
      4. group Id
        FG003
        num Subjects
        0
      type
      NOT COMPLETED
    title
    Overall Study

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice